Nascent Biotech Inc NBIO

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.

OTCQB:NBIO - Post by User

Nascent Biotech Inc

Bullboard Posts

Post by ok2buyon Sep 01, 2020 7:56pm

101 Views

Post# 31491547

NBIO

Starting Phase 1 trial with Pritumumab (Prit.) for brain cancer. In partnership with university researchers and other clinicians as Prit. may also have an application for Covid. Insiders have tripled or even greater, the number of shares they own in the company since 2018-19. The company has recently reduced their outstanding liabilities. Just raised cash through a private equity funding. Despite all the positive news as of late, stock has moved lower on very little volume. In my opinion, at this price acquiring the stock here has been significantly derisked. Be patient on your bid, float is low and may not get your fill in one order. As always, do your own dd./ok2

Bullboard Posts

Canada Goose appoints first creative director